Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03028246 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT03028246 · ClinicalTrials.gov record · last posted 2026-06-29

A Feasibility Safety Study of Benign Centrally-Located Intracranial Tumors in Pediatric and Young Adult Subjects

StatusRecruiting
PhaseNot applicable
SponsorInSightec
Started2017-02-28
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The goal of this prospective, non-randomized, single-arm, feasibility study is to develop data to evaluate the safety and feasibility of ExAblate 4000 treatment of benign intracranial tumors which require clinical intervention in pediatric and young adult subjects. Indication of Use: Ablation of benign intracranial tumors in children and young adults which are ExAblate accessible.

Amendment record 22 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 22 times since 2017-01-18; most recent amendment 2026-06-25. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

Trial Details
NCT Number NCT03028246
Lead Sponsor InSightec
Conditions Benign Centrally-Located Intracranial Tumors
Enrollment 20 participants
Start Date 2017-02-28
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-29